 | • レポートコード：MRC2-11QY07681 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は転移性卵巣がん治療薬のグローバル市場について調査・分析したレポートです。種類別（E-7449、クリゾチニブ、CMB-305、G-305、LV-305、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別転移性卵巣がん治療薬の競争状況、市場シェア ・世界の転移性卵巣がん治療薬市場：種類別市場規模 2015年-2020年（E-7449、クリゾチニブ、CMB-305、G-305、LV-305、その他） ・世界の転移性卵巣がん治療薬市場：種類別市場規模予測 2021年-2026年（E-7449、クリゾチニブ、CMB-305、G-305、LV-305、その他） ・世界の転移性卵巣がん治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の転移性卵巣がん治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の転移性卵巣がん治療薬市場分析：米国、カナダ ・ヨーロッパの転移性卵巣がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの転移性卵巣がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の転移性卵巣がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの転移性卵巣がん治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Adgero Biopharmaceuticals Inc、Cellceutix Corporation、Eisai Co., Ltd.、F. Hoffmann-La Roche Ltd.、Immune Design Corp.、Millennium Pharmaceuticals Inc、MolMed S.p.A.、Natco Pharma Limited、Northwest Biotherapeutics, Inc.、Pfizer Inc.、Richter Gedeon Nyrt.、Sumitomo Dainippon Pharma Co., Ltd.、VG Life Sciences, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Metastatic Ovarian Cancer Drug Market
The global Metastatic Ovarian Cancer Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Metastatic Ovarian Cancer Drug Scope and Market Size
Metastatic Ovarian Cancer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Ovarian Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Metastatic Ovarian Cancer Drug market is segmented into
E-7449
Crizotinib
CMB-305
G-305
LV-305
Others
Segment by Application, the Metastatic Ovarian Cancer Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Metastatic Ovarian Cancer Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Metastatic Ovarian Cancer Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Metastatic Ovarian Cancer Drug Market Share Analysis
Metastatic Ovarian Cancer Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Metastatic Ovarian Cancer Drug business, the date to enter into the Metastatic Ovarian Cancer Drug market, Metastatic Ovarian Cancer Drug product introduction, recent developments, etc.
The major vendors covered:
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
1 Study Coverage
1.1 Metastatic Ovarian Cancer Drug Product Introduction
1.2 Market Segments
1.3 Key Metastatic Ovarian Cancer Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Type
1.4.2 E-7449
1.4.3 Crizotinib
1.4.4 CMB-305
1.4.5 G-305
1.4.6 LV-305
1.4.7 Others
1.5 Market by Application
1.5.1 Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Metastatic Ovarian Cancer Drug Market Size, Estimates and Forecasts
2.1.1 Global Metastatic Ovarian Cancer Drug Revenue 2015-2026
2.1.2 Global Metastatic Ovarian Cancer Drug Sales 2015-2026
2.2 Global Metastatic Ovarian Cancer Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Metastatic Ovarian Cancer Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Metastatic Ovarian Cancer Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Metastatic Ovarian Cancer Drug Competitor Landscape by Players
3.1 Metastatic Ovarian Cancer Drug Sales by Manufacturers
3.1.1 Metastatic Ovarian Cancer Drug Sales by Manufacturers (2015-2020)
3.1.2 Metastatic Ovarian Cancer Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Metastatic Ovarian Cancer Drug Revenue by Manufacturers
3.2.1 Metastatic Ovarian Cancer Drug Revenue by Manufacturers (2015-2020)
3.2.2 Metastatic Ovarian Cancer Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Metastatic Ovarian Cancer Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Metastatic Ovarian Cancer Drug Revenue in 2019
3.2.5 Global Metastatic Ovarian Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Metastatic Ovarian Cancer Drug Price by Manufacturers
3.4 Metastatic Ovarian Cancer Drug Manufacturing Base Distribution, Product Types
3.4.1 Metastatic Ovarian Cancer Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Metastatic Ovarian Cancer Drug Product Type
3.4.3 Date of International Manufacturers Enter into Metastatic Ovarian Cancer Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Metastatic Ovarian Cancer Drug Market Size by Type (2015-2020)
4.1.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2015-2020)
4.1.2 Global Metastatic Ovarian Cancer Drug Revenue by Type (2015-2020)
4.1.3 Metastatic Ovarian Cancer Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Metastatic Ovarian Cancer Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Type (2021-2026)
4.2.3 Metastatic Ovarian Cancer Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Metastatic Ovarian Cancer Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Metastatic Ovarian Cancer Drug Market Size by Application (2015-2020)
5.1.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2015-2020)
5.1.2 Global Metastatic Ovarian Cancer Drug Revenue by Application (2015-2020)
5.1.3 Metastatic Ovarian Cancer Drug Price by Application (2015-2020)
5.2 Metastatic Ovarian Cancer Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Metastatic Ovarian Cancer Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Metastatic Ovarian Cancer Drug by Country
6.1.1 North America Metastatic Ovarian Cancer Drug Sales by Country
6.1.2 North America Metastatic Ovarian Cancer Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Metastatic Ovarian Cancer Drug Market Facts & Figures by Type
6.3 North America Metastatic Ovarian Cancer Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Metastatic Ovarian Cancer Drug by Country
7.1.1 Europe Metastatic Ovarian Cancer Drug Sales by Country
7.1.2 Europe Metastatic Ovarian Cancer Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Metastatic Ovarian Cancer Drug Market Facts & Figures by Type
7.3 Europe Metastatic Ovarian Cancer Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Metastatic Ovarian Cancer Drug by Region
8.1.1 Asia Pacific Metastatic Ovarian Cancer Drug Sales by Region
8.1.2 Asia Pacific Metastatic Ovarian Cancer Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Metastatic Ovarian Cancer Drug Market Facts & Figures by Type
8.3 Asia Pacific Metastatic Ovarian Cancer Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Metastatic Ovarian Cancer Drug by Country
9.1.1 Latin America Metastatic Ovarian Cancer Drug Sales by Country
9.1.2 Latin America Metastatic Ovarian Cancer Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Metastatic Ovarian Cancer Drug Market Facts & Figures by Type
9.3 Central & South America Metastatic Ovarian Cancer Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Metastatic Ovarian Cancer Drug by Country
10.1.1 Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country
10.1.2 Middle East and Africa Metastatic Ovarian Cancer Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Metastatic Ovarian Cancer Drug Market Facts & Figures by Type
10.3 Middle East and Africa Metastatic Ovarian Cancer Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Adgero Biopharmaceuticals Inc
11.1.1 Adgero Biopharmaceuticals Inc Corporation Information
11.1.2 Adgero Biopharmaceuticals Inc Description and Business Overview
11.1.3 Adgero Biopharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
11.1.5 Adgero Biopharmaceuticals Inc Related Developments
11.2 Cellceutix Corporation
11.2.1 Cellceutix Corporation Corporation Information
11.2.2 Cellceutix Corporation Description and Business Overview
11.2.3 Cellceutix Corporation Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Products Offered
11.2.5 Cellceutix Corporation Related Developments
11.3 Eisai Co., Ltd.
11.3.1 Eisai Co., Ltd. Corporation Information
11.3.2 Eisai Co., Ltd. Description and Business Overview
11.3.3 Eisai Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
11.3.5 Eisai Co., Ltd. Related Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Products Offered
11.4.5 F. Hoffmann-La Roche Ltd. Related Developments
11.5 Immune Design Corp.
11.5.1 Immune Design Corp. Corporation Information
11.5.2 Immune Design Corp. Description and Business Overview
11.5.3 Immune Design Corp. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Products Offered
11.5.5 Immune Design Corp. Related Developments
11.6 Millennium Pharmaceuticals Inc
11.6.1 Millennium Pharmaceuticals Inc Corporation Information
11.6.2 Millennium Pharmaceuticals Inc Description and Business Overview
11.6.3 Millennium Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
11.6.5 Millennium Pharmaceuticals Inc Related Developments
11.7 MolMed S.p.A.
11.7.1 MolMed S.p.A. Corporation Information
11.7.2 MolMed S.p.A. Description and Business Overview
11.7.3 MolMed S.p.A. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Products Offered
11.7.5 MolMed S.p.A. Related Developments
11.8 Natco Pharma Limited
11.8.1 Natco Pharma Limited Corporation Information
11.8.2 Natco Pharma Limited Description and Business Overview
11.8.3 Natco Pharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Products Offered
11.8.5 Natco Pharma Limited Related Developments
11.9 Northwest Biotherapeutics, Inc.
11.9.1 Northwest Biotherapeutics, Inc. Corporation Information
11.9.2 Northwest Biotherapeutics, Inc. Description and Business Overview
11.9.3 Northwest Biotherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Products Offered
11.9.5 Northwest Biotherapeutics, Inc. Related Developments
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Corporation Information
11.10.2 Pfizer Inc. Description and Business Overview
11.10.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Products Offered
11.10.5 Pfizer Inc. Related Developments
11.1 Adgero Biopharmaceuticals Inc
11.1.1 Adgero Biopharmaceuticals Inc Corporation Information
11.1.2 Adgero Biopharmaceuticals Inc Description and Business Overview
11.1.3 Adgero Biopharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
11.1.5 Adgero Biopharmaceuticals Inc Related Developments
11.12 Sumitomo Dainippon Pharma Co., Ltd.
11.12.1 Sumitomo Dainippon Pharma Co., Ltd. Corporation Information
11.12.2 Sumitomo Dainippon Pharma Co., Ltd. Description and Business Overview
11.12.3 Sumitomo Dainippon Pharma Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sumitomo Dainippon Pharma Co., Ltd. Products Offered
11.12.5 Sumitomo Dainippon Pharma Co., Ltd. Related Developments
11.13 VG Life Sciences, Inc.
11.13.1 VG Life Sciences, Inc. Corporation Information
11.13.2 VG Life Sciences, Inc. Description and Business Overview
11.13.3 VG Life Sciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 VG Life Sciences, Inc. Products Offered
11.13.5 VG Life Sciences, Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Metastatic Ovarian Cancer Drug Market Estimates and Projections by Region
12.1.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Regions 2021-2026
12.2 North America Metastatic Ovarian Cancer Drug Market Size Forecast (2021-2026)
12.2.1 North America: Metastatic Ovarian Cancer Drug Sales Forecast (2021-2026)
12.2.2 North America: Metastatic Ovarian Cancer Drug Revenue Forecast (2021-2026)
12.2.3 North America: Metastatic Ovarian Cancer Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Metastatic Ovarian Cancer Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Metastatic Ovarian Cancer Drug Sales Forecast (2021-2026)
12.3.2 Europe: Metastatic Ovarian Cancer Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Metastatic Ovarian Cancer Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Metastatic Ovarian Cancer Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Metastatic Ovarian Cancer Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Metastatic Ovarian Cancer Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Metastatic Ovarian Cancer Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Metastatic Ovarian Cancer Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Metastatic Ovarian Cancer Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Metastatic Ovarian Cancer Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Metastatic Ovarian Cancer Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Metastatic Ovarian Cancer Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Metastatic Ovarian Cancer Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Metastatic Ovarian Cancer Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Metastatic Ovarian Cancer Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Metastatic Ovarian Cancer Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Metastatic Ovarian Cancer Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Metastatic Ovarian Cancer Drug Market Segments
Table 2. Ranking of Global Top Metastatic Ovarian Cancer Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of E-7449
Table 5. Major Manufacturers of Crizotinib
Table 6. Major Manufacturers of CMB-305
Table 7. Major Manufacturers of G-305
Table 8. Major Manufacturers of LV-305
Table 9. Major Manufacturers of Others
Table 10. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Metastatic Ovarian Cancer Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Metastatic Ovarian Cancer Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Metastatic Ovarian Cancer Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Metastatic Ovarian Cancer Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Metastatic Ovarian Cancer Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Metastatic Ovarian Cancer Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Metastatic Ovarian Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Metastatic Ovarian Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Ovarian Cancer Drug as of 2019)
Table 19. Metastatic Ovarian Cancer Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Metastatic Ovarian Cancer Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Metastatic Ovarian Cancer Drug Price (2015-2020) (USD/Pcs)
Table 22. Metastatic Ovarian Cancer Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Metastatic Ovarian Cancer Drug Product Type
Table 24. Date of International Manufacturers Enter into Metastatic Ovarian Cancer Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Metastatic Ovarian Cancer Drug Sales Share by Type (2015-2020)
Table 28. Global Metastatic Ovarian Cancer Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Metastatic Ovarian Cancer Drug Revenue Share by Type (2015-2020)
Table 30. Metastatic Ovarian Cancer Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Metastatic Ovarian Cancer Drug Sales Share by Application (2015-2020)
Table 33. North America Metastatic Ovarian Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Metastatic Ovarian Cancer Drug Sales Market Share by Country (2015-2020)
Table 35. North America Metastatic Ovarian Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Metastatic Ovarian Cancer Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Table 39. North America Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Metastatic Ovarian Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Metastatic Ovarian Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Metastatic Ovarian Cancer Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Metastatic Ovarian Cancer Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Metastatic Ovarian Cancer Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Metastatic Ovarian Cancer Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Metastatic Ovarian Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Metastatic Ovarian Cancer Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Metastatic Ovarian Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Metastatic Ovarian Cancer Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Metastatic Ovarian Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Table 73. Adgero Biopharmaceuticals Inc Corporation Information
Table 74. Adgero Biopharmaceuticals Inc Description and Major Businesses
Table 75. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Adgero Biopharmaceuticals Inc Product
Table 77. Adgero Biopharmaceuticals Inc Recent Development
Table 78. Cellceutix Corporation Corporation Information
Table 79. Cellceutix Corporation Description and Major Businesses
Table 80. Cellceutix Corporation Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Cellceutix Corporation Product
Table 82. Cellceutix Corporation Recent Development
Table 83. Eisai Co., Ltd. Corporation Information
Table 84. Eisai Co., Ltd. Description and Major Businesses
Table 85. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Eisai Co., Ltd. Product
Table 87. Eisai Co., Ltd. Recent Development
Table 88. F. Hoffmann-La Roche Ltd. Corporation Information
Table 89. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 90. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. F. Hoffmann-La Roche Ltd. Product
Table 92. F. Hoffmann-La Roche Ltd. Recent Development
Table 93. Immune Design Corp. Corporation Information
Table 94. Immune Design Corp. Description and Major Businesses
Table 95. Immune Design Corp. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Immune Design Corp. Product
Table 97. Immune Design Corp. Recent Development
Table 98. Millennium Pharmaceuticals Inc Corporation Information
Table 99. Millennium Pharmaceuticals Inc Description and Major Businesses
Table 100. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Millennium Pharmaceuticals Inc Product
Table 102. Millennium Pharmaceuticals Inc Recent Development
Table 103. MolMed S.p.A. Corporation Information
Table 104. MolMed S.p.A. Description and Major Businesses
Table 105. MolMed S.p.A. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. MolMed S.p.A. Product
Table 107. MolMed S.p.A. Recent Development
Table 108. Natco Pharma Limited Corporation Information
Table 109. Natco Pharma Limited Description and Major Businesses
Table 110. Natco Pharma Limited Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Natco Pharma Limited Product
Table 112. Natco Pharma Limited Recent Development
Table 113. Northwest Biotherapeutics, Inc. Corporation Information
Table 114. Northwest Biotherapeutics, Inc. Description and Major Businesses
Table 115. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Northwest Biotherapeutics, Inc. Product
Table 117. Northwest Biotherapeutics, Inc. Recent Development
Table 118. Pfizer Inc. Corporation Information
Table 119. Pfizer Inc. Description and Major Businesses
Table 120. Pfizer Inc. Metastatic Ovarian Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Pfizer Inc. Product
Table 122. Pfizer Inc. Recent Development
Table 123. Richter Gedeon Nyrt. Corporation Information
Table 124. Richter Gedeon Nyrt. Description and Major Businesses
Table 125. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Richter Gedeon Nyrt. Product
Table 127. Richter Gedeon Nyrt. Recent Development
Table 128. Sumitomo Dainippon Pharma Co., Ltd. Corporation Information
Table 129. Sumitomo Dainippon Pharma Co., Ltd. Description and Major Businesses
Table 130. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Sumitomo Dainippon Pharma Co., Ltd. Product
Table 132. Sumitomo Dainippon Pharma Co., Ltd. Recent Development
Table 133. VG Life Sciences, Inc. Corporation Information
Table 134. VG Life Sciences, Inc. Description and Major Businesses
Table 135. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. VG Life Sciences, Inc. Product
Table 137. VG Life Sciences, Inc. Recent Development
Table 138. Global Metastatic Ovarian Cancer Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 139. Global Metastatic Ovarian Cancer Drug Sales Market Share Forecast by Regions (2021-2026)
Table 140. Global Metastatic Ovarian Cancer Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 141. Global Metastatic Ovarian Cancer Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 142. North America: Metastatic Ovarian Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 143. North America: Metastatic Ovarian Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Europe: Metastatic Ovarian Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 145. Europe: Metastatic Ovarian Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Asia Pacific: Metastatic Ovarian Cancer Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 147. Asia Pacific: Metastatic Ovarian Cancer Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 148. Latin America: Metastatic Ovarian Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 149. Latin America: Metastatic Ovarian Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 150. Middle East and Africa: Metastatic Ovarian Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 151. Middle East and Africa: Metastatic Ovarian Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 153. Key Challenges
Table 154. Market Risks
Table 155. Main Points Interviewed from Key Metastatic Ovarian Cancer Drug Players
Table 156. Metastatic Ovarian Cancer Drug Customers List
Table 157. Metastatic Ovarian Cancer Drug Distributors List
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Ovarian Cancer Drug Product Picture
Figure 2. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020 & 2026
Figure 3. E-7449 Product Picture
Figure 4. Crizotinib Product Picture
Figure 5. CMB-305 Product Picture
Figure 6. G-305 Product Picture
Figure 7. LV-305 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Metastatic Ovarian Cancer Drug Report Years Considered
Figure 14. Global Metastatic Ovarian Cancer Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Metastatic Ovarian Cancer Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Metastatic Ovarian Cancer Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region in 2019
Figure 19. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region in 2019
Figure 21. Global Metastatic Ovarian Cancer Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Metastatic Ovarian Cancer Drug Revenue in 2019
Figure 23. Metastatic Ovarian Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2019
Figure 26. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type in 2019
Figure 28. Global Metastatic Ovarian Cancer Drug Market Share by Price Range (2015-2020)
Figure 29. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2019
Figure 31. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application in 2019
Figure 33. North America Metastatic Ovarian Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Metastatic Ovarian Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Metastatic Ovarian Cancer Drug Sales Market Share by Country in 2019
Figure 36. North America Metastatic Ovarian Cancer Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Metastatic Ovarian Cancer Drug Market Share by Type in 2019
Figure 42. North America Metastatic Ovarian Cancer Drug Market Share by Application in 2019
Figure 43. Europe Metastatic Ovarian Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Metastatic Ovarian Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Country in 2019
Figure 46. Europe Metastatic Ovarian Cancer Drug Revenue Market Share by Country in 2019
Figure 47. Germany Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Metastatic Ovarian Cancer Drug Market Share by Type in 2019
Figure 58. Europe Metastatic Ovarian Cancer Drug Market Share by Application in 2019
Figure 59. Asia Pacific Metastatic Ovarian Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Metastatic Ovarian Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Metastatic Ovarian Cancer Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Metastatic Ovarian Cancer Drug Revenue Market Share by Region in 2019
Figure 63. China Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Metastatic Ovarian Cancer Drug Market Share by Type in 2019
Figure 86. Asia Pacific Metastatic Ovarian Cancer Drug Market Share by Application in 2019
Figure 87. Latin America Metastatic Ovarian Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Metastatic Ovarian Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Metastatic Ovarian Cancer Drug Sales Market Share by Country in 2019
Figure 90. Latin America Metastatic Ovarian Cancer Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Metastatic Ovarian Cancer Drug Market Share by Type in 2019
Figure 98. Latin America Metastatic Ovarian Cancer Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Metastatic Ovarian Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Metastatic Ovarian Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Metastatic Ovarian Cancer Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Metastatic Ovarian Cancer Drug Market Share by Application in 2019
Figure 111. North America Metastatic Ovarian Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Metastatic Ovarian Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Metastatic Ovarian Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Metastatic Ovarian Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Metastatic Ovarian Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Metastatic Ovarian Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Metastatic Ovarian Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Metastatic Ovarian Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Metastatic Ovarian Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
卵巣がん遺伝子治療の世界市場（～2026年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…- 転移性膵臓がん治療の世界市場（～2026年） Metastatic pancreatic cancer treatment, when cancer spreads outside of the pancreas, surgery may or may not be recommended. It’s more common for oncologists to recommend systemic treatments (which can circulate throughout the entire body and destroy cancerous cells in multiple locations) for metasta…
- 転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…
- 卵巣がんの世界市場（～2026年） Ovarian cancer is a type of cancer that begins in the ovaries. Ovarian cancer is the most common type of cancer among women. Epithelial tumor, stromal tumor and germ cell tumors are the type of ovarian cancer. North America dominates the global market for ovarian cancer due to large number of aging …
- 転移性大腸癌手術の世界市場（～2026年） Colorectal cancer is the third most common type cancer and represents 9.7% of total cancer cases across the globe. According to American Cancer Society colorectal cancer is treatable and curable when it is localized to the bowel. However, colorectal cancer cancers that have spread to other body part…